NCT02709330View on ClinicalTrials.gov

ALS Reversals - Lunasin Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 13, 2017

Study Completion Date

September 13, 2017

Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
DRUG

Lunasin Regimen

LunaRich X Capsules, Reliv Now, ProVantage

OTHER

Historical control

Matched historical controls will be identified from the PatientsLikeMe database.

Trial Locations (1)

27705

Duke Medicine / Neurology, Durham

All Listed Sponsors
lead

Richard Bedlack, M.D., Ph.D.

OTHER

NCT02709330 - ALS Reversals - Lunasin Regimen | Biotech Hunter | Biotech Hunter